米氮平治疗广泛性焦虑障碍的开放性研究

An open trial of mirtazapine in the treatment of generalized anxiety disorder

目的 研究米氮平治疗广泛性焦虑障碍(GAD)的疗效和安全性。方法 对符合CCMD 3 广泛性焦虑诊断标准的患者26例使用30mg/d米氮平治疗6周,在0、2、4、6周评定汉密尔顿焦虑量表 (HAMA,14项),并评定疗效、记录出现的不良反应。结果 米氮平能显著改善GAD患者的精神性焦 虑和躯体性焦虑,治疗结束时的显效率达65.4%,有效率达88.5%。最常见的不良反应均为思睡和体 重增加。结论 米氮平对广泛性焦虑症疗效肯定,不良反应少。

Objective: To explore the clinical efficacy and side effects of mirtazapine in the treatment of generalized anxiety disorder. Methods: 26 patients who met CCMD-3 criteria for generalized anxiety disorder were involved in this study. They were treated with mirtazapine for six weeks. Efficacy and side effects were evaluated with Hamilton Anxiety Scale (HAMA) before and after treatment. Results: The efficacy rate of was 88.5%, in which 65.4% were improved markedly. Conclusion: Mirtazapine is effective in the treatment of generalized anxiety disorder and produces fewer side effects.